Published in Neuropharmacology on August 01, 1986
Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol (1988) 1.02
Evidence that RU 24969-induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5-HT1B receptor. Br J Pharmacol (1993) 0.86
Behavioral sensitization and cross-sensitization between methylphenidate amphetamine, and 3,4-methylenedioxymethamphetamine (MDMA) in female SD rats. Eur J Pharmacol (2011) 0.86
Quipazine reduces food intake in the rat by activation of 5-HT2-receptors. Br J Pharmacol (1988) 0.79
Serotonin/dopamine interactions in a hyperactive mouse: reduced serotonin receptor 1B activity reverses effects of dopamine transporter knockout. PLoS One (2014) 0.77
Effects of repeated exposure to MDMA on 5HT1a autoreceptor function: behavioral and neurochemical responses to 8-OHDPAT. Psychopharmacology (Berl) (2013) 0.77
Actions of 5-HT1 ligands on excitatory synaptic transmission in the hippocampus of alert rats. Br J Pharmacol (1990) 0.77
Postsynaptic 5-HT1B receptors modulate electroshock-induced generalised seizures in rats. Br J Pharmacol (2005) 0.75
Social work in general practice. Lancet (1968) 9.80
Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology (1986) 5.83
(-)Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature (1980) 3.33
8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur J Pharmacol (1983) 2.45
Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol Sci (1995) 2.35
Parkinson's disease: prospects for improved drug therapy. Trends Pharmacol Sci (1997) 2.00
SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology (1997) 1.76
The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol (1984) 1.74
A functional correlate for the dihydropyridine binding site in rat brain. Nature (1985) 1.68
Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. Trends Pharmacol Sci (1989) 1.63
Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther (2000) 1.56
Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. Br J Pharmacol (2000) 1.55
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970). J Med Chem (2000) 1.42
Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients. Lancet (1980) 1.41
Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR. Br J Pharmacol (1999) 1.38
SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol (1997) 1.28
Cardiovascular response to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in the rat: site of action and pharmacological analysis. J Cardiovasc Pharmacol (1987) 1.26
Stereoselective blockade at [3H]5-HT binding sites and at the 5-HT autoreceptor by propranolol. Eur J Pharmacol (1984) 1.20
Formation of compound I by the reaction of catalase with peroxoacetic acid. Biochem J (1972) 1.19
Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype. Proc Natl Acad Sci U S A (1992) 1.19
Evidence for regulation of body temperature in rats by dopamine D2 receptor and possible influence of D1 but not D3 and D4 receptors. Neuropharmacology (2003) 1.14
Molecular cloning and characterization of two novel retinoic acid-inducible orphan G-protein-coupled receptors (GPRC5B and GPRC5C). Genomics (2000) 1.13
The behavioural effects of corticotropin-releasing factor-related peptides in rats. Psychopharmacology (Berl) (1998) 1.11
Is group B streptococcal screening during pregnancy justified? Br J Obstet Gynaecol (1985) 1.10
Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719. Br J Pharmacol (1998) 1.10
Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur J Pharmacol (2001) 1.09
Using multimedia virtual patients to enhance the clinical curriculum for medical students. Stud Health Technol Inform (1998) 1.09
Innovative solutions to novel drug development in mental health. Neurosci Biobehav Rev (2013) 1.08
8-Hydroxy-2-(di-n-propylamino) tetralin is devoid of activity at the 5-hydroxytryptamine autoreceptor in rat brain. Implications for the proposed link between the autoreceptor and the [3H] 5-HT recognition site. Naunyn Schmiedebergs Arch Pharmacol (1984) 1.07
The putative 5-HT1 receptor agonist, RU 24969, inhibits the efflux of 5-hydroxytryptamine from rat frontal cortex slices by stimulation of the 5-HT autoreceptor. J Pharm Pharmacol (1985) 1.03
The expression of GABA(B1) and GABA(B2) receptor subunits in the cNS differs from that in peripheral tissues. Neuroscience (2000) 1.03
5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist. J Med Chem (1999) 1.03
Interactions between dopamine and 5-HT3 receptors suggest new treatments for psychosis and drug addiction. Trends Pharmacol Sci (1989) 1.02
Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig. Eur J Pharmacol (1997) 0.99
SB-224289--a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity. Br J Pharmacol (1998) 0.97
Cloning and characterization of human NTT5 and v7-3: two orphan transporters of the Na+/Cl- -dependent neurotransmitter transporter gene family. Genomics (2000) 0.97
(R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist. J Med Chem (1998) 0.96
[(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol (2000) 0.95
Effects of albumin, amino acids, and clofibrate on the uptake of tryptophan by the rat brain. J Neurochem (1980) 0.95
The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat. Br J Pharmacol (1998) 0.95
Modulation of seizure susceptibility in the mouse by the strychnine-insensitive glycine recognition site of the NMDA receptor/ion channel complex. Br J Pharmacol (1990) 0.94
The pharmacological sensitivity of a touchscreen-based visual discrimination task in the rat using simple and perceptually challenging stimuli. Psychopharmacology (Berl) (2011) 0.93
5-CT stimulation of adenylyl cyclase activity in guinea-pig hippocampus: evidence for involvement of 5-HT7 and 5-HT1A receptors. Br J Pharmacol (1999) 0.93
[3H]-SB-269970 radiolabels 5-HT7 receptors in rodent, pig and primate brain tissues. Neuropharmacology (2002) 0.92
Quantitative mRNA analysis of five C-terminal splice variants of the human 5-HT4 receptor in the central nervous system by TaqMan real time RT-PCR. Brain Res Mol Brain Res (2001) 0.92
Group B streptococcal colonisation and the outcome of pregnancy. J Infect (1986) 0.91
Effect of chronic antidepressant treatment and subsequent withdrawal on [3H]-5-hydroxytryptamine and [3H]-spiperone binding in rat frontal cortex and serotonin receptor mediated behaviour. Psychopharmacology (Berl) (1983) 0.91
Pharmacological characterization of extracellular acidification rate responses in human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol (1999) 0.91
Mediation of the discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) by the putative 5-HT1A receptor. Eur J Pharmacol (1987) 0.91
Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. Br J Pharmacol (1999) 0.91
Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology (Berl) (1995) 0.90
Hydrosyringomyelia and its management in childhood. Neurosurgery (1987) 0.90
The glycine/NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents. Br J Pharmacol (1993) 0.89
K+-evoked [3H]-5-HT release from rat frontal cortex slices: the effect of 5-HT agonists and antagonists. Biochem Pharmacol (1982) 0.89
Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist. Br J Pharmacol (2000) 0.89
Propranolol in schizophrenia. II. Clinical and biochemical aspects of combining propranolol with chlorpromazine. Br J Psychiatry (1981) 0.89
Formation of catalase compound I by reaction with peroxoacetic acid: pH changes in unbuffered systems. Biochem J (1974) 0.89
A comparison of an improved o-phthalaldehyde fluorometric method and high pressure liquid chromatography in the determination of brain 5-hydroxyindoles of rats treated with L-tryptophan and p-chlorophenyl-alanine. Br J Pharmacol (1981) 0.89
MDL 72832: a potent and stereoselective ligand at central and peripheral 5-HT1A receptors. Eur J Pharmacol (1988) 0.89
5-Hydroxytryptamine1A but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. J Pharmacol Exp Ther (1992) 0.88
Pharmacological characterisation of human 5-HT2 receptor subtypes. Eur J Pharmacol (2001) 0.88
Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor. J Med Chem (1988) 0.87
Metitepine distinguishes two receptors mediating inhibition of [3H]-5-hydroxytryptamine release in guinea pig hippocampus. Naunyn Schmiedebergs Arch Pharmacol (1992) 0.87
Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit. Behav Pharmacol (2003) 0.87
Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N,N-dimethyltryptamine in the rat. Eur J Pharmacol (1985) 0.87
Alpha 2-adrenoceptor antagonist activity may account for the effects of buspirone in an anticonflict test in the rat. Eur J Pharmacol (1988) 0.87
SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology (2001) 0.87
Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors. Naunyn Schmiedebergs Arch Pharmacol (1997) 0.86
Central nervous actions of beta-adrenoreceptor antagonists. Clin Sci Mol Med (1978) 0.86
R-(+)-HA-966, a glycine/NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine. Br J Pharmacol (1991) 0.86
An investigation of the 5-HT1D receptor binding affinity of 5-hydroxytryptamine, 5-carboxyamidotryptamine and sumatriptan in the central nervous system of seven species. Eur J Pharmacol (1992) 0.85
Stereoselective blockade at the 5-HT autoreceptor and inhibition of radioligand binding to central 5-HT recognition sites by the optical isomers of methiothepin. Neuropharmacology (1986) 0.85
Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue. Br J Pharmacol (2000) 0.85
Kaposi's sarcoma in a transplanted kidney. Transplantation (1989) 0.84
Blockade of the central 5-HT autoreceptor by beta-adrenoceptor antagonists. Eur J Pharmacol (1986) 0.84
Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol (1998) 0.84
4-substituted-3-phenylquinolin-2(1H)-ones: acidic and nonacidic glycine site N-methyl-D-aspartate antagonists with in vivo activity. J Med Chem (1997) 0.84
The calcium channel activator, Bay K 8644, enhances K+-evoked efflux of acetylcholine and noradrenaline from rat brain slices. Naunyn Schmiedebergs Arch Pharmacol (1985) 0.83
Differential effects of 5-HT1B/1D receptor antagonists in dorsal and median raphe innervated brain regions. Eur J Pharmacol (1998) 0.83
Effects of tryptophan and portocaval anastomosis on activity and brain tryptophan metabolism [proceedings]. Br J Pharmacol (1977) 0.83
One-trial tolerance to the effects of chlordiazepoxide on the elevated plus maze may be due to locomotor habituation, not repeated drug exposure. Psychopharmacology (Berl) (1994) 0.83
L-694,247: a potent 5-HT1D receptor agonist. Br J Pharmacol (1993) 0.83
The discriminative stimulus properties of (+)-HA-966, an antagonist at the glycine/N-methyl-D-aspartate receptor. Eur J Pharmacol (1990) 0.83
Centrally active 5-HT receptor agonists and antagonists. Neurosci Biobehav Rev (1992) 0.83
Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol (1999) 0.83
Disruption in the temporal sequence of regional ventricular contraction. I. Characteristics and incidence in coronary artery disease. Circulation (1980) 0.83
Characterization of the binding of [3H]-SB-204269, a radiolabelled form of the new anticonvulsant SB-204269, to a novel binding site in rat brain membranes. Br J Pharmacol (1997) 0.83
Spiropiperidines as high-affinity, selective sigma ligands. J Med Chem (1992) 0.82
Activation of the 5-HT1A receptor subtype increases rat plasma ACTH concentration. Eur J Pharmacol (1988) 0.82
GR127935 acts as a partial agonist at recombinant human 5-HT1D alpha and 5-HT1D beta receptors. Eur J Pharmacol (1996) 0.82
Characterization of MDL 73005EF as a 5-HT1A selective ligand and its effects in animal models of anxiety: comparison with buspirone, 8-OH-DPAT and diazepam. Br J Pharmacol (1990) 0.82
The effects of GR127935, a putative 5-HT1D receptor antagonist, on brain 5-HT metabolism, extracellular 5-HT concentration and behaviour in the guinea pig. Neuropharmacology (1995) 0.82